83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population

Saved in:
Bibliographic Details
Published inImmuno-oncology technology Vol. 16; p. 100187
Main Authors Mazzarella, L., Nicolo, E., Esposito, A., Crimini, E., Tini, G., Uliano, J., Corti, C., Trillo Aliaga, P.M., Valenza, C., Repetto, M., Antonarelli, G., Minchella, I., Belli, C., Locatelli, M.A., Criscitiello, C., Curigliano, G.
Format Journal Article
LanguageEnglish
Published 01.12.2022
Online AccessGet full text

Cover

ArticleNumber 100187
Author Minchella, I.
Belli, C.
Tini, G.
Mazzarella, L.
Trillo Aliaga, P.M.
Repetto, M.
Crimini, E.
Antonarelli, G.
Nicolo, E.
Locatelli, M.A.
Valenza, C.
Uliano, J.
Corti, C.
Esposito, A.
Curigliano, G.
Criscitiello, C.
Author_xml – sequence: 1
  givenname: L.
  surname: Mazzarella
  fullname: Mazzarella, L.
– sequence: 2
  givenname: E.
  surname: Nicolo
  fullname: Nicolo, E.
– sequence: 3
  givenname: A.
  surname: Esposito
  fullname: Esposito, A.
– sequence: 4
  givenname: E.
  surname: Crimini
  fullname: Crimini, E.
– sequence: 5
  givenname: G.
  surname: Tini
  fullname: Tini, G.
– sequence: 6
  givenname: J.
  surname: Uliano
  fullname: Uliano, J.
– sequence: 7
  givenname: C.
  surname: Corti
  fullname: Corti, C.
– sequence: 8
  givenname: P.M.
  surname: Trillo Aliaga
  fullname: Trillo Aliaga, P.M.
– sequence: 9
  givenname: C.
  surname: Valenza
  fullname: Valenza, C.
– sequence: 10
  givenname: M.
  surname: Repetto
  fullname: Repetto, M.
– sequence: 11
  givenname: G.
  surname: Antonarelli
  fullname: Antonarelli, G.
– sequence: 12
  givenname: I.
  surname: Minchella
  fullname: Minchella, I.
– sequence: 13
  givenname: C.
  surname: Belli
  fullname: Belli, C.
– sequence: 14
  givenname: M.A.
  surname: Locatelli
  fullname: Locatelli, M.A.
– sequence: 15
  givenname: C.
  surname: Criscitiello
  fullname: Criscitiello, C.
– sequence: 16
  givenname: G.
  surname: Curigliano
  fullname: Curigliano, G.
BookMark eNpNkE1OwzAQhS1UJErpDVjMki5SHOfPXVZVgUiRQLT7yHEmxCWJIzst6q4HAYmz9SSklAWreXqaefP0XZNBoxsk5NalU5e64f1mqnSHspwyylhvUZdHF2TIghl1es0H__QVGVu7oZSyaOZTTofkm3svsC4R4rreNugYrESHOYh8h8Yi4A6bDu7i1_lyAol6x0qVWuewktpg7yerCai831GFQgvHw2e7NXg8fMHpxILtjG7eqj0Ia7VUv9kfqitBbzupawTVgIC2FP2v2Ilj6IwSFbS63fZFlG5uyGUhKovjvzki64flevHkJM-P8WKeOHLmRo4IKEMpQy4iLNwsF5KH1C8CdMMiKpjgKALmZT2iqMh4EAWC-ixEFmZZEHqCeSPin2Ol0dYaLNLWqFqYferS9MQ53aRnzumJc3rm7P0AfBd3WA
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1016/j.iotech.2022.100187
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2590-0188
ExternalDocumentID 10_1016_j_iotech_2022_100187
GroupedDBID .1-
.FO
0SF
AAEDW
AALRI
AAXUO
AAYXX
ADVLN
AEXQZ
AFJKZ
AFRHN
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
CITATION
EBS
EJD
FDB
GROUPED_DOAJ
M41
M~E
NCXOZ
OK1
ROL
RPM
Z5R
ID FETCH-LOGICAL-c917-a502ecc68a7ef1bdac8604f5e16f7f2a8ea523b2027fb8575a0426e26bb563a23
ISSN 2590-0188
IngestDate Thu Sep 26 18:48:22 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c917-a502ecc68a7ef1bdac8604f5e16f7f2a8ea523b2027fb8575a0426e26bb563a23
OpenAccessLink https://doi.org/10.1016/j.iotech.2022.100187
ParticipantIDs crossref_primary_10_1016_j_iotech_2022_100187
PublicationCentury 2000
PublicationDate 2022-12-00
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-00
PublicationDecade 2020
PublicationTitle Immuno-oncology technology
PublicationYear 2022
SSID ssj0002794080
Score 2.2505302
SourceID crossref
SourceType Aggregation Database
StartPage 100187
Title 83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuiKd4VnPgQGU5ctaPOMeqBDWoQYgGqbdo115Th8qJ0uRATv0hIPGP-A_9JczM-lUaIcrFSiab1SbzaXZ29psZIV7rzNMa_VhXqkHqBjqKXO1J5fo61KGX9bRJKd4x_hAdfg7en4Qnnc6vFmtpvdLdZLM1r-R_tIoy1Ctlyd5As_WkKMDXqF98oobx-U86jv2PTJkYUZKHcTkvBR1IRU2Wz43DxZnYhfy0P6Tj_1H-1ZzlXMj4mMpX8mdE3hs4eWppQxSFLfkPB4v10lRv3jo0yTnllsyLL2ffHFXqtaKvz9cr_IlcgkQ5i1PcHJ2ROxo5ti3Iou4T1vaGed1zd14kthLU6lqcf6w2G7UkhhYHELrNNQp9hQ15LRtaBprN26mltm9Z3hpaxjikbPFF2BTiGY3oc7YBYNdskVW2vG2Me9xxcOs-YUMWs25OtTDoTkrKbjP8alnuP7bLmsRY8eNmUzvLlGaZ2lluidsSLV_cCh_N-JZ3EHjcza9efZXOyZzD68tpuUstv2dyX9wrDyywb9H3QHRM8VDcGZeUjEfiJ4IQEIRwFYRQghAYhPCG0LMHDQCBAYjyo-M9aMAHlxffCXaXFz-AAQcV4KABHBDgoAQc5AUoYMABAQ4YcNAA7rGYvBtODg7dsu2HmwzQZVKhJ9GuRLHqG7QVqUriyAuy0PSirJ9JFRsVSl9T0C7T1F9WURjAyAhtTuQr6T8RO8W8ME8FpCYcRP2-8ozWgQoilaQmTWSc9RLpJbH3TLjVnztd2OIu079p9fkNx78Qdxs0vxQ7q-XavEIfdqV3Ofazy-j4DakbnMU
link.rule.ids 315,783,787,867,27938,27939
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=83P+The+Immune-related+adverse+event+%28IRAE%29+Likelihood+Score+%28ILS%29+identifies+%E2%80%9Cpure%E2%80%9D+IRAEs+strongly+associated+with+outcome+in+a+phase+I-II+trial+population&rft.jtitle=Immuno-oncology+technology&rft.au=Mazzarella%2C+L.&rft.au=Nicolo%2C+E.&rft.au=Esposito%2C+A.&rft.au=Crimini%2C+E.&rft.date=2022-12-01&rft.issn=2590-0188&rft.eissn=2590-0188&rft.volume=16&rft.spage=100187&rft_id=info:doi/10.1016%2Fj.iotech.2022.100187&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_iotech_2022_100187
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2590-0188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2590-0188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2590-0188&client=summon